Apogenix AG

Apogenix AG: Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model

Apogenix’ Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus Standard of Care in Newly Diagnosed Glioblastoma Multiforme

Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept

Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients

Apogenix Receives EUR 20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19

Apogenix AG: COVID-19 targeted treatment trial launched in Vienna

Apogenix Advances Clinical Development of CD95L Inhibitor Asunercept in European COVID-19 Phase II Trial

Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients

Apogenix to Present at AACR Virtual Annual Meeting II

Apogenix to Present New Data on Asunercept at ESMO Immuno-Oncology Congress

Strong Quality of Life Data for Apogenix’ Asunercept Published in Journal of Neuro-Oncology

Apogenix to Present at Several Upcoming International Conferences

ESMO and Apogenix Collaborate on ‘Recurrent Glioblastoma Management: Challenges and Opportunities’ Colloquium

Publication in Human Vaccines & Immunotherapeutics Illustrates the Advantages of Hexavalent CD40 Agonists in Targeting CD40 in Immuno-Oncology

Publication in Cancer Management and Research Underlines the Potential of Apogenix’ Asunercept for the Treatment of Other Malignancies Beyond Glioblastoma and MDS

Excellent Preclinical Efficacy Data of Apogenix’ HERA-GITRL Published in Journal for ImmunoTherapy of Cancer

Apogenix to Present at Four Upcoming International Conferences

Apogenix Announces Oral and Poster Presentations at Upcoming International Conferences

Apogenix to Present at Five Upcoming International Conferences

Preclinical Efficacy Data of Apogenix’ HERA-CD40L Published in Journal of Immunotherapy

Preclinical Efficacy Data of Apogenix’ HERA-CD27L Published in Frontiers in Oncology

Apogenix Strengthens Patent Position for Lead Drug Candidate Asunercept

Apogenix Provides Update on Clinical Development of Asunercept

Apogenix Granted Orphan Designation by the European Commission for Asunercept to Treat Myelodysplastic Syndromes

Apogenix Granted PRIME designation by European Medicines Agency for Asunercept to Treat Glioblastoma

Apogenix to Present at Three Upcoming International Conferences

Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie

Apogenix Presents Data on Novel Hexavalent TNF Receptor Agonists (HERA) at the Upcoming Annual Meeting of the American Association for Cancer Research (AACR)

Apogenix Reports Final Phase I MDS Data at this Year’s American Society of Hematology (ASH) Meeting

Apogenix Reports Significant Progress in Collaboration with CANbridge